These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29499174)

  • 21. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H; Ji B; Chung H; Kim HC
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SEROUS MACULAR DETACHMENT IN BEST DISEASE: A Masquerade Syndrome.
    Zatreanu L; Freund KB; Leong BCS; Yu HG; Teke MY; Yzer S; Sadda SR; Sarraf D
    Retina; 2020 Aug; 40(8):1456-1470. PubMed ID: 31613838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
    Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
    Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.
    Dugel PU; Jhaveri CD; Chakravarthy U; Wykoff CC; Singh RP; Hamilton R; Weissgerber G; Mulyukov Z; Holz FG
    Retina; 2022 Mar; 42(3):511-518. PubMed ID: 34923515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
    Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
    Inan S; Baysal Z; Inan UU
    Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
    [No Abstract]   [Full Text] [Related]  

  • 28. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RANIBIZUMAB IN PIGMENT EPITHELIAL TEARS SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Prospective Study.
    Larsen PP; Oishi A; Bedar MS; Heymer PKR; Clemens CR; König S; Gutfleisch M; Pauleikhoff D; Eter N; Wolf A; Holz FG; Krohne TU
    Retina; 2019 Dec; 39(12):2369-2377. PubMed ID: 30198967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between foveal microstructure and visual outcome in age-related macular degeneration.
    Shin HJ; Chung H; Kim HC
    Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
    Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
    Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration.
    Nguyen V; Daien V; Guymer R; Young S; Hunyor A; Fraser-Bell S; Hunt A; Gillies MC; Barthelmes D;
    Ophthalmology; 2019 Jan; 126(1):64-74. PubMed ID: 30149035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
    Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
    Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB; Lund-Andersen H; Sander B; Larsen M
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
    Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB
    Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of Retinal Thickness and Swept-Source Optical Coherence Tomography Angiography Derived Vascular Changes in Patients with Neovascular Age-Related Macular Degeneration.
    Told R; Reiter GS; Schranz M; Reumueller A; Hacker V; Mittermueller TJ; Roberts PK; Sacu S; Schmidt-Erfurth U
    Curr Eye Res; 2021 Jul; 46(7):1002-1009. PubMed ID: 33211556
    [No Abstract]   [Full Text] [Related]  

  • 38. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity.
    Chang YS; Han JI; Yoo SJ; Lew YJ; Kim JH
    Korean J Ophthalmol; 2014 Dec; 28(6):466-72. PubMed ID: 25435749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
    Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.